Petros Ouzounakis

Mr. Petros Ouzounakis


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2022 in Cureus
Verified
Journal Article
Open access
CSChristos Sialakis
Christos Sialakis
CIChristos Iliadis
Christos Iliadis
AFAikaterini Frantzana
Aikaterini Frantzana
POPetros Ouzounakis
Petros Ouzounakis
LKLAMBRINI KOURKOUTA
LAMBRINI KOURKOUTA
Idiopathic sudden sensorineural hearing loss (ISSHL) is a common condition characterized by hearing threshold reduction, most often of unknown causes. The patient experiences a sudden reduction of the hearing threshold in one or both ears. Steroids are the mainstream of the treatment. This study aims to investigate the effectiveness of intratympanic steroid administration compared with systemic administration and the combination of the two steroid treatments in the hearing recovery of patients with idiopathic sudden sensorineural hearing loss. We searched electronic databases such as PubMed, ScienceDirect, CINAHL, Cochrane (Central), Ovid, and Medline from August 31, 2021, to November 31, 2021, and from February 5 to 10, 2022. We included 12 randomized controlled trials (RCTs) and performed a meta-analysis comparing the efficiency in the hearing recovery of intratympanic versus systemic steroid treatment, systemic versus combined, and intratympanic versus combined steroid treatment. The results of the intratympanic versus systemic steroid therapy comparison showed no actual difference in efficiency and no statistical significance (odds ratio: 1.07 (Mantel-Haenszel (M-H), fixed, 95% confidence interval (CI): 0.76-1.51)). Systemic steroid treatment was inferior to combined steroid treatment and was the only outcome with statistical significance (odds ratio: 0.55 (M-H, fixed, 95% CI: 0.38-0.80)). Intratympanic steroid treatment was inferior to combined steroid treatment, although the results were not statistically significant (odds ratio: 0.65 (M-H, fixed, 95% CI: 0.37-1.16)). In conclusion, systemic steroid therapy was inferior to combined steroid therapy. The comparison of intratympanic with systemic therapy and intratympanic with combined therapy showed no statistical significance. Further research is needed with more RCTs, and side effects should be considered.

31 October 2018
Verified
Book Chapter
Open access
PDF file
LKLAMBRINI KOURKOUTA
LAMBRINI KOURKOUTA
POPetros Ouzounakis
Petros Ouzounakis
Ioanna V. PapathanasiouIoanna V. Papathanasiou
Ioanna V. Papathanasiou
KKKoukourikos Konstantinos
Koukourikos Konstantinos
TKTsaras Konstantinos
Tsaras Konstantinos
ATARETI TSALOGLIDOU
ARETI TSALOGLIDOU
Introduction: Sleep is an important part of people’s lives and proper sleep is a prerequisite for good health.

26 July 2022 in Cureus
Verified
Journal Article
Open access
CSChristos Sialakis
Christos Sialakis
PSPanagiota Antoniou Sialaki
Panagiota Antoniou Sialaki
AFAikaterini Frantzana
Aikaterini Frantzana
CIChristos Iliadis
Christos Iliadis
POPetros Ouzounakis
Petros Ouzounakis
LKLambrini Kourkouta
Lambrini Kourkouta
Background: The treatment of allergic rhinitis is important due to the burden that the disease causes globally. The objective of this review is to explore the efficiency of house dust mite and grass pollen extracts in allergic rhinitis treatment. Methods: We performed research in electronic databases and searched relevant articles on PubMed, CINAHL, OVID, ScienceDirect, Cochrane CENTRAL, and MEDLINE. We used keywords such as ‘allergic rhinitis', ‘sublingual immunotherapy’, ‘randomized controlled trials', ‘grass pollen’, 'allergen immunotherapy’, and ‘house dust mite’. We included nine randomized controlled trials (RCTs). Quality assessment of included studies was performed independently by two authors. Results: We included nine eligible RCTs in this review. Five RCTs were about grass pollen extracts and four RCTs were about house dust mite extracts. Most of the studies reported positive results and suggested further evaluation of sublingual immunotherapy (SLIT) treatment. Grass pollen extracts mostly used were Dactylis glomerata, Poa pratensis, Lolium perenne, Anthoxanthum odoratum, Phleum pratense, and Parietaria. House dust mite extracts used were from Dermatophagoides pteronyssinus and Dermatophagoides farina. According to the quality assessment, no bias was observed in the included studies. Conclusions: Although sublingual allergen immunotherapy shows a benefit compared to placebo in the treatment of allergic rhinitis and rhino-conjunctivitis in adults, the results are interpreted with caution due to the high heterogenicity among studies in treatment protocols and dosing. More standardization among studies is needed.

27 December 2014 in American Journal of Nursing Science
Verified
Journal Article
Open access
PDF file
POPetros Ouzounakis
Petros Ouzounakis
MAMonios Alexandros
Monios Alexandros
VMVakalopoulou Marina
Vakalopoulou Marina
DADimitriadou Alexandra
Dimitriadou Alexandra
Introduction: Unemployment as a problem exceeds the individual level and is the result of structural mismatches of each society. Purpose: In the present retrospective study are investigated the effects of the unemployment, especially among young people, and the prevention thereof. Material and methods: The sample consisted of recent articles on the topic, found mainly in the electronic database Medline, the Greek Academic Libraries Link (HEAL-Link) and through search engine "Google scholar". Results: The effects of the unemployment are proving disastrous for the psychology of young people, and decreases their self-esteem, they feel losing part of their social role, their relationships are made dysfunctional and eventually losing their quality of life. Conclusions: It is necessary the support for the unemployed youth of a team of experts, so that young people be enable to reevaluate their self-image and promote their quality of life.

19 August 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Vasilis PetrakisVasilis Petrakis
Vasilis Petrakis
PRPetros Rafailidis
Petros Rafailidis
Andreas G. TsantesAndreas G. Tsantes
Andreas G. Tsantes
DTDimitrios Themelidis
Dimitrios Themelidis
NBNikoleta Babaka
Nikoleta Babaka
PPPeriklis Panagopoulos
Periklis Panagopoulos
Background/Objectives: The rise of extended-spectrum β-lactamase (ESBL)-producing Enterobacterales has led to an increased carbapenem use, raising concerns regarding selection pressure for carbapenem-resistant organisms. Ceftolozane–tazobactam (C/T) is a potential effective carbapenem-sparing alternative. This single-centre retrospective study evaluated the clinical effectiveness and mortality predictors of ceftolozane–tazobactam versus meropenem as definitive targeted therapy for ESBL-producing Enterobacterales bloodstream infections (BSIs). Methods: We conducted a single-center retrospective analysis of adult hospitalized patients between January 2022 and February 2024 who presented with BSIs caused by ESBL-producing Enterobacterales. Patients (N = 185) were included if they received either C/T (n = 73) or optimized high-dose meropenem (n = 112) for at least 48 h. The primary clinical endpoint was all-cause 30-day mortality. Secondary endpoints included clinical success (cure), in-hospital mortality, treatment duration, microbiological eradication, and infection recurrence rates. A multivariable logistic regression model was executed to determine independent predictors of 30-day mortality. Results: Escherichia coli (54.1%) and Klebsiella pneumoniae (35.1%) were the primary pathogens. The raw clinical success rate was higher with C/T than meropenem (83.6% vs. 71.6%, p = 0.078). Unadjusted 30-day mortality was 12.3% for C/T and 19.6% for meropenem (p = 0.342). Zero recurrences occurred with C/T compared to an 8.0% recurrence rate with meropenem (0/73 [0.0%] in C/T vs. 9/112 [8.0%] in meropenem, p = 0.015). In the multivariable logistic regression analysis, definitive targeted treatment with C/T was independently associated with lower odds of all-cause 30-day mortality (Adjusted Odds Ratio [aOR] 0.60; 95% Confidence Interval [CI] 0.33–0.92; p = 0.022). Conversely, independent clinical mortality risks included male gender (p = 0.027), baseline SOFA score (p = 0.001), septic shock (p = 0.001), and an unknown primary infection source (p = 0.001). Conclusions: In this single-center retrospective observational cohort, definitive targeted therapy with ceftolozane–tazobactam was associated with favorable clinical success and lower adjusted 30-day mortality compared to meropenem in patients with ESBL Enterobacterales BSIs. These observational data support further prospective evaluation of C/T as a potential carbapenem-sparing option. Prospective randomized controlled trials are required to confirm these findings before clinical practice algorithms are modified.